Clinical trials: COVID-19
Coronavirus Infection
Covid-19, Hospitalized, PatIents, Nasafytol
The objective of this study is to evaluate the effect and safety of NASAFYTOL® on COVID-19 positive hospitalized patients as a supportive supplementation to standard-of-care in improving clinical parameters safely during hospital…
- Trial name
- NCT04844658
- Testing
- NASAFYTOL®, FULTIUM® -D3 800, Strandard of care treatment
- Where
- Belgium
- Volunteers
- 51 people
- Sponsor
- Tilman S.A.
Stress, Psychological
Distress in Crisis Situations During COVID-19
There are many scales for screening or assessing the impact of a disease. These scales are generally used to diagnose or assess the severity of a disease and are carried out at the request of a physician by the patient.
- Trial name
- NCT04337047
- Testing
- questionnaire assesment
- Where
- France
- Volunteers
- 2,000 people, healthy volunteers welcome
- Sponsor
- Wefight
COVID-19
A Prospective, Phase II Study to Evaluate Safety of 101-PGC-005 ('005) for Moderate to Severe COVID-19 Disease Along With Standard of Care
In December 2019, a novel pneumonia caused by a previously unknown pathogen emerged in Wuhan, China. The pathogen was soon identified as a novel coronavirus (SARS-CoV-2), which is closely related to severe acute respiratory…
- Trial name
- NCT05195749
- Testing
- 101-PGC-005 ('005) + SOC
- Where
- Israel
- Volunteers
- 3 people
- Sponsor
- 101 Therapeutics
Viral Infection COVID-19
Pharmacokinetics and Bioequivalence of Aterixen 100 mg Tablets and Aterixen 100 mg Film-coated Tablets in Healthy Volunteers
1. Comparative evaluation of the safety of the drug Aterixen 100 mg tablets (Valenta Pharm JSC, Russia) and Aterixen 100 mg film-coated tablets (Valenta Pharm JSC, Russia) administered in single doses under fasting conditions in…
- Trial name
- NCT06096571
- Testing
- Aterixen
- Where
- Russia
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Valenta Pharm JSC
Coronavirus Disease 2019 (COVID-19)
A Study of AK119 (Anti-CD73 Antibody), a Treatment for COVID-19, in Healthy Subjects
This is a first-in-human (FIH), Phase 1, single-center, randomized, double-blind, placebo-controlled, single ascending dose study to evaluate the safety, tolerability, PK and immunogenicity of AK119, a humanized monoclonal…
- Trial name
- NCT04516564
- Testing
- AK119
- Where
- New Zealand
- Volunteers
- 29 people, healthy volunteers welcome
- Sponsor
- Akesobio Australia Pty Ltd
Covid19
The Efficacy and Safety of SCTA01 in Hospitalized Patients With Severe COVID-19
The study is a multicenter, adaptive, randomized, double-blinded and placebo-controlled Phase II/III trial, and will be conducted globally.
- Trial name
- NCT04644185
- Testing
- SCTA01
- Where
- 7 sites in United States, Argentina and 5 more
- Volunteers
- 102 people
- Sponsor
- Sinocelltech Ltd.
Mild to Moderate COVID-19
A Study to Evaluate the Efficacy, Safety, and Concentration of SNS812 in Mild to Moderate COVID-19 Patients
A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetics of SNS812 in Participants with Mild to Moderate COVID-19
- Trial name
- NCT05941793
- Testing
- MBS-COV
- Where
- 5 sites in United States, Taiwan
- Volunteers
- 135 people
- Sponsor
- Oneness Biotech Co., Ltd.
SARS-CoV-2
A Study to Evaluate Safety and Immunogenicity of mRNA-1273 Vaccine to Prevent COVID-19 in Adult Organ Transplant Recipients and in Healthy Adult Participants
This is an open-label study to evaluate the safety, reactogenicity, and immunogenicity of mRNA-1273 Severe Acute Respiratory Syndrome coronavirus (SARS-CoV-2) vaccine in adults with a kidney or liver solid organ transplant (SOT)…
- Trial name
- NCT04860297
- Testing
- mRNA-1273
- Where
- 15 sites in United States
- Volunteers
- 234 people, healthy volunteers welcome
- Sponsor
- ModernaTX, Inc.
Covid19
Safety and the Efficacy of MesenCure for the Treatment of Pulmonary Manifestations of COVID-19
An open label clinical study to evaluate the safety and the efficacy of MesenCure, an allogeneic cell therapy product, for the treatment of the pulmonary manifestations in COVID19 patients
- Trial name
- NCT04716998
- Testing
- MesenCure
- Where
- 3 sites in Israel
- Volunteers
- 50 people
- Sponsor
- BonusBio Group Ltd
COVID-19
101-PGC-005 for the Treatment of COVID-19
This is a prospective, randomized, comparative, multi-centric, adaptive design clinical study to evaluate efficacy, safety, and tolerability of 101-PGC-005 ('005) when used alongside standard of care (SOC) for the treatment of…
- Trial name
- NCT05656521
- Testing
- 101-PGC-005, Dexamethasone
- Where
- 5 sites in India
- Volunteers
- 62 people
- Sponsor
- 101 Therapeutics
COVID-19
To Evaluate Safety and Efficacy of EC-18 in COVID-19 Infection to Pneumonia
Prevention of COVID-19 infection to severe pneumonea or ARDS
- Trial name
- NCT04500132
- Testing
- EC-18
- Where
- South Korea
- Volunteers
- 63 people
- Sponsor
- Enzychem Lifesciences Corporation
Long COVID
Utilizing Novel Blood RNA Biomarkers as a Diagnostic Tool in the Identification of Long COVID-19
The Primary objective of this study is to determine, using unblinded samples, if it is possible to develop an algorithm for the classification of specific blood RNA from patients with long COVID together and separately from the…
- Trial name
- NCT06311435
- Testing
- RNA Biomarker Blood Test
- Where
- 3 sites in United States
- Volunteers
- 224 people, healthy volunteers welcome
- Sponsor
- MaxWell Clinic, PLC
SARS (Severe Acute Respiratory Syndrome), Covid19
Longitudinal Follow-up of a Population Cohort in a French City With High SARS-CoV-2 Circulation, in Early 2020 [COVID-19]
An initial retrospective epidemiological investigation was conducted in a city north of France after the diagnosis of the first case of COVID-19 on February 2020.
- Trial name
- COVID-OISE (NCT04644159)
- Testing
- Human biological samples
- Where
- 2 sites in France
- Volunteers
- 1,000 people, healthy volunteers welcome
- Sponsor
- Institut Pasteur
SARS-CoV-2 Virus Infection
COV-COMPARE Immunogenicity of Vaccine VLA2001 Compared to AZD1222
This is a multicentre, randomized, observer-blind, active-controlled, superiority, study in adults to compare the immunogenicity of VLA2001 to AZD1222 in terms of GMT of SARS-CoV-2-specific neutralising antibodies.
- Trial name
- COV-COMPARE (NCT04864561)
- Testing
- VLA2001, AZD1222, VLA2001 - adolescent part
- Where
- 31 sites in United Kingdom
- Volunteers
- 4,034 people, healthy volunteers welcome
- Sponsor
- Valneva Austria GmbH
COVID-19
A Dose Escalation Phase 1 Study Evaluating the Safety and Pharmacokinetics of an Inhaled COVID-19 Inhibitor Delcetravir in Healthy Subjects
This study will be a single center, Phase I, randomized, double-blind, placebo controlled, single and multiple ascending dose (SAD/MAD) study evaluating the safety, tolerability, and PK of Delcetravir after administration via…
- Trial name
- NCT05453279
- Testing
- Delcetravir dry powder inhaler
- Volunteers
- 8 people, healthy volunteers welcome
- Sponsor
- Esfam Biotech Pty Ltd
Corona Virus Infection
Nitric Oxide Releasing Solutions to Prevent and Treat Mild/Moderate COVID-19 Infection
This is a multi-center, randomized, controlled, phase II clinical efficacy study evaluating a novel Nitric Oxide Releasing Solution (NORS) treatment for the prevention and treatment of COVID-19 in healthcare workers at risk of…
- Trial name
- NOCOVID (NCT04337918)
- Testing
- NORS (Nitric Oxide Releasing Solution)
- Where
- 5 sites in Canada
- Volunteers
- 143 people, healthy volunteers welcome
- Sponsor
- Sanotize Research and Development corp.
Coronavirus Disease 2019 (COVID-19)
A Study to Learn About the Study Medicine Paxlovid (Nirmatrelvir + Ritonavir) in Adults Aged 60 and Older Living in Korean Long-term Care Hospitals Who Have COVID-19
The purpose of this study is to learn about the effects of the study medicine (called Paxlovid) for the possible treatment of COVID-19 in older adults who live in long-term care hospitals (LTCHs) in Korea.
- Trial name
- NCT07089680
- Testing
- Nirmatrelvir/Ritonavir
- Where
- 7 sites in South Korea
- Volunteers
- 937 people
- Sponsor
- Pfizer
COVID-19, SARS-CoV-2
Parent Study: Study Understanding Pre-Exposure pRophylaxis of NOvel Anitbodies (SUPERNOVA) Sub-study: Study Understanding Pre-Exposure pRophylaxis of NOvel Anitbodies (SUPERNOVA Sub-study)
AZD3152, a single mAb, is being developed to have broad neutralizing activity across known SARS-CoV-2 variants of concern for pre-exposure prophylaxis of COVID-19.
- Trial name
- SUPERNOVA (NCT05648110)
- Testing
- AZD5156 (Parent study Sentinel Safety Cohort), EVUSHELD™ (Parent study Main Cohort), AZD3152 (Parent study Main Cohort)
- Where
- 215 sites in United States, Australia and 16 more
- Volunteers
- 3,882 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Coronavirus Disease (COVID-19)
Survey of the Moderna COVID-19 Vaccine in People at High-Risk of Developing Severe COVID-19 Symptoms
This study is a survey of the Moderna COVID-19 vaccine in Japanese people at high risk of developing severe COVID-19 symptoms. The study sponsor will not be involved in how the participants are treated but will provide…
- Trial name
- NCT04892888
- Testing
- COVID-19 Vaccine
- Where
- Japan
- Volunteers
- healthy volunteers welcome
- Sponsor
- Takeda
COVID-19 Disease
ABNCoV2 Vaccine in Adult Subjects Previously Vaccinated for SARS-CoV-2
This trial is composed of a randomized, double-blind, active controlled component (Part A) and an open-label, single-arm component (Part B) conducted in parallel.
- Trial name
- NCT05329220
- Testing
- ABNCoV2, Comirnaty
- Where
- 57 sites in United States, Belgium and 1 more
- Volunteers
- 4,205 people, healthy volunteers welcome
- Sponsor
- Bavarian Nordic
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.